Acromegaly - The Annual Endocrine Society of Australia Seminar ...

More documents

Recommendations

Info

Somatostatin analog resistance Consider higher dose SSA
SSA resistant acromegaly: Increase the Dose? Giustina et al, Eur J Endocrinol (2009), 61:331-338 24-week randomized trial SSA resistant acromegaly despite ≥6 month conventional SSA therapy. high-dose (60 mg/28 days) or high-frequency (30 mg/21 days) octreotide i.m. injection Normal IGF-1 in 4 out <strong>of</strong> 11 (36%) HD and none <strong>of</strong> the HF Mazziotti G et al. Eur J Endocrinol 2011;164:341-347 Posthoc analysis Glucose status worsened in 25% Worsening glucose associated with inadequate GH/IGF-1 reduction
Page 1 and 2: Acromegaly Endocrine Society of Aus
Page 3 and 4: Case 1 45 yo male sent to PCP beca
Page 5 and 6: MRI scan: microadenoma
Page 7 and 8: Biochemical Diagnostic Testing Ran
Page 9 and 10: Therapy Surgery is primary therape
Page 11 and 12: Post-Surgical Assessment (A) Immed
Page 13 and 14: Case 1, contd. 12 week serum IGF-1
Page 15 and 16: Case 2 48 yo female with joint pai
Page 17 and 18: Pre-operative Medical Therapy? Imp
Page 19 and 20: Peri-operative risk with acromegaly
Page 21 and 22: Therapy of Residual Disease after S
Page 23 and 24: Biochemical Monitoring on Medical T
Page 25 and 26: Medical Therapy Somatostatin Analo
Page 27 and 28: Growth Hormone Receptor Antagonist
Page 29: Case 2, contd Because of residual
Page 33 and 34: van der Lely, Eur J Endo 2011;164:3
Page 35 and 36: Radiation Therapy: Types Conventio
Page 37 and 38: Back to case… Macroadenoma CS inv
Page 39 and 40: Case 3 Macroadenoma CS involvement
Page 41 and 42: Additional Monitoring: Comorbiditie
Page 43 and 44: Additional Monitoring: Comorbiditie
Page 45 and 46: Pregnancy and Acromegaly Limited d
Page 47: Pregnancy and Acromegaly Once pati

Acromegaly - The Annual Endocrine Society of Australia Seminar ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?